According to filings with the U.S. Securities and Exchange Commission, Epicrispr Biotechnologies has raised $90 Million in new Series C funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Octagon Capital, Janus Henderson Investors, Fidelity Management & Research Company, Cormorant Asset Management, Duquesne Family Office, Sanofi Ventures, funds managed by abrdn Inc., Angelini Ventures, Readout Capital

About Epicrispr Biotechnologies
Epicrispr Biotechnologies is a biotechnology company pioneering programmable epigenetic and gene modulating therapies that regulate gene expression without permanently altering DNA. It is a leading epigenome editing company built on compact, non cutting CRISPR/dCas technologies and a proprietary Gene Expression Modulation System (GEMS), which enables precise, durable control of gene activity to unlock first in class treatments for previously untreatable conditions. The company is advancing an expansive therapeutic pipeline of epigenetic gene therapies for serious diseases, with a particular focus on neuromuscular disorders such as facioscapulohumeral muscular dystrophy (FSHD), where its lead program EPI 321 is in clinical or late preclinical development. Epicrispr has been recognized as a top early stage innovator, including being named to Fierce Biotechs Fierce 15 list, and it has secured substantial venture financing across multiple funding rounds to support its research, clinical trials, and platform development. In addition to its internal pipeline, the company also pursues strategic collaborations, such as partnering with Kite Pharma on next generation CAR T cell therapies, reinforcing its position as a cutting edge player in the genetic and epigenetic medicine landscape.

To learn more, visit https://epicrispr.com/
Linkedin: https://www.linkedin.com/company/epicrispr-biotechnologies

Contact:
Amber Salzman, Chief Executive Officer
https://www.linkedin.com/in/ambersalzman

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.